hydroxychloroquine has been researched along with Multiple Sclerosis in 13 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS)." | 8.31 | Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis. ( Camara-Lemarroy, C; Gohill, J; Koch, M; Silva, C; Yong, VW, 2023) |
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 5.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "Teriflunomide, the active metabolite of leflunomide, is a disease-modifying therapy drug used for the treatment of multiple sclerosis (MS), yet the complications associated with this drug remain not fully understood." | 5.41 | Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report. ( Feng, J; Qin, X; Xu, K; Yang, S; Yu, G; Zhang, M; Zheng, P, 2023) |
| "In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS)." | 4.31 | Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis. ( Camara-Lemarroy, C; Gohill, J; Koch, M; Silva, C; Yong, VW, 2023) |
| "In our patient, sarcoidosis developed after 3 years of continuous recombinant interferon-beta therapy, dosed 3 times a week." | 2.48 | Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review. ( Chakravarty, SD; Crow, MK; Harris, ME; Schreiner, AM, 2012) |
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 1.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "The coexistence of systemic lupus erythematosus (SLE) and multiple sclerosis (MS) in the same individual has rarely been described." | 1.40 | Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history. ( Amoiridis, G; Bertsias, G; Boumpas, DT; Fanouriakis, A; Mastorodemos, V; Pamfil, C; Papadaki, E; Plaitakis, A; Sidiropoulos, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Camara-Lemarroy, C | 1 |
| Silva, C | 1 |
| Gohill, J | 1 |
| Yong, VW | 3 |
| Koch, M | 3 |
| Xu, K | 1 |
| Zhang, M | 1 |
| Yang, S | 1 |
| Yu, G | 1 |
| Zheng, P | 1 |
| Qin, X | 1 |
| Feng, J | 1 |
| Gemcioglu, E | 1 |
| Davutoglu, M | 1 |
| Ozdemir, EE | 1 |
| Erden, A | 1 |
| Parrotta, E | 1 |
| Kister, I | 1 |
| Charvet, L | 1 |
| Sammarco, C | 1 |
| Saha, V | 1 |
| Charlson, RE | 1 |
| Howard, J | 1 |
| Gutman, JM | 1 |
| Gottesman, M | 1 |
| Abou-Fayssal, N | 1 |
| Wolintz, R | 1 |
| Keilson, M | 1 |
| Fernandez-Carbonell, C | 1 |
| Krupp, LB | 1 |
| Zhovtis Ryerson, L | 1 |
| Mazloumfard, F | 1 |
| Mirian, M | 1 |
| Eftekhari, SM | 2 |
| Aliomrani, M | 2 |
| Brown, D | 1 |
| Moezzi, D | 1 |
| Dong, Y | 1 |
| Safaei, HA | 1 |
| Faissner, S | 1 |
| Mahjoub, Y | 1 |
| Mishra, M | 1 |
| Haupeltshofer, S | 1 |
| Hahn, JN | 1 |
| Gold, R | 1 |
| Metz, LM | 1 |
| Ben-Hur, T | 1 |
| Fanouriakis, A | 1 |
| Mastorodemos, V | 1 |
| Pamfil, C | 1 |
| Papadaki, E | 1 |
| Sidiropoulos, P | 1 |
| Plaitakis, A | 1 |
| Amoiridis, G | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Chakravarty, SD | 1 |
| Harris, ME | 1 |
| Schreiner, AM | 1 |
| Crow, MK | 1 |
| SULLI, G | 1 |
| VARRONE, F | 1 |
| LOUYOT, P | 1 |
| GAUCHER, A | 1 |
| JEANBLANC, J | 1 |
| MONTET, Y | 1 |
| Fritzsche, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)[NCT02913157] | Phase 2 | 35 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Multiple Sclerosis
| Article | Year |
|---|---|
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
Topics: Adult; Female; Humans; Hydroxychloroquine; Leflunomide; Lupus Erythematosus, Cutaneous; Multiple Scl | 2023 |
Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Interferon-beta; Methotrexate; | 2012 |
[EXTRAMALARIAL THERAPUETIC APPLICATIONS OF ANTIMALARIAL DRUGS. 1. CLINICAL UTILIZATIONS].
Topics: Amodiaquine; Antimalarials; Chloroquine; Collagen Diseases; Dermatology; Drug Utilization; Epilepsy; | 1963 |
10 other studies available for hydroxychloroquine and Multiple Sclerosis
| Article | Year |
|---|---|
Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Topics: Biomarkers; Clinical Trials, Phase II as Topic; Glial Fibrillary Acidic Protein; Humans; Hydroxychlo | 2023 |
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Coronavirus Infections; | 2020 |
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID- | 2020 |
Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis.
Topics: Animals; Cuprizone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression; Hydroxychl | 2020 |
Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis.
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; | 2021 |
Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model.
Topics: Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Hydroxychloroqu | 2021 |
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Topics: Animals; B-Lymphocytes; Cell Proliferation; Disease Models, Animal; Encephalomyelitis, Autoimmune, E | 2018 |
Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-De | 2014 |
[EVALUATION OF LONG-TERM THERAPY WITH CHLOROQUINE AND HYDROXYCHLOROQUINE IN RHEUMATOLOGY].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Humans; Hydrarthrosis; Hydroxychloroqui | 1964 |
Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable?
Topics: Animals; Anti-Bacterial Agents; Borrelia burgdorferi Group; Chronic Disease; Drug Therapy, Combinati | 2005 |